Partner
In the News
John Shakow comments on the recent ruling in the Genesis case that could potentially expand 340B-eligible prescriptions
November 7, 2023
| 340B ReportGo to the article
Explore King & Spalding
Capabilities
Special Matters & Government Investigations
Capabilities
FDA & Life Sciences